medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 3

<< Back Next >>

Med Int Mex 2020; 36 (3)

Restrictive myocardiopathy by amyloidosis

García-Arias MR, Rodríguez-Gómez MÁ, Cedillo-Urbina MR, Aguiñiga-Rodríguez A, Gonzaga-López TI, Alavez-Torres E, Medina-Galindo J, Rangel-Rojo FJ, Terán-González JÓ, Balam-Ortiz EO

Language: Spanish
References: 23
Page: 431-438
PDF size: 328.74 Kb.


ABSTRACT

Background: Amyloidosis is a systemic disease which is caused by an extracellular deposit of amyloid fibrils of different proteins that self-assembled with an inadequate coupling that traduces an altered structural conformation. One of the main clinical manifestations is cardiac amyloidosis that is produced by the infiltration of the myocardium by amyloid fibril; that lead to a diastolic dysfunction and heart failure with a poor prognosis.
Clinical case: A 66-year-old female patient with previous diagnosis of breast cancer, that received surgical treatment and chemotherapy. She arrived at the emergency room presenting dyspnea at rest associated to a restrictive myocardiopathy of infiltrative etiology.
Conclusions: Cardiac amyloidosis implies a diagnostic and therapeutic challenge because due to it is a clinical manifestation of a systemic disease, its manifestation is heterogeneous.


REFERENCES

  1. Bhogal S, Ladia V, Sitwala P, Cook E, Bajaj K, et al. Cardiac amyloidosis: An updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol 2018;43(1):10- 34. doi: 10.1016/j.cpcardiol.2017.04.003.

  2. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016;387(10038):2641-2645. doi: 10.1016/ S0140-6736(15)01274-X.

  3. Esplin BL, Gertz MA. Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol 2013;38(2):53-96. doi: 10.1016/j.cpcardiol.2012.11.002.

  4. Kyriakou P, Mouselimis D, Tsarouchas A, Rigopoulos A, Bakogiannis C, et al. Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers. BMC Cardiovasc Disord 2018;181:1-11. doi: 10.1186/ s12872-018-0952-8.

  5. Kyle RA. Amyloidosis. Clin Haematol 1982 Feb;11(1):151- 80.

  6. Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol 2013;161(4):525-532. doi: 10.1111/bjh.12286.

  7. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753(1):11-22. oi: 10.1016/j.bbapap.2005.08.014.

  8. Urieli-Shoval S, Linke RP,Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7(1):64-69. doi: 10.1097/00062752-200001000-00012.

  9. Falk RH. Diagnosis and management of the cardiac amyloidosis. Circulation 2005;112(13):2047-60. https://doi. org/10.1161/CIRCULATIONAHA.104.489187.

  10. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar. Updates in cardiac amyloidosis: A review. J Am Heart Assoc 2012;1(2):1-13. doi: 10.1161/JAHA.111.000364.

  11. Gutierrez PS, Fernandes F, Mady C, Higuchi Mide L. Clinical, electrocardiographic and echocardiographic findings in significant cardiac amyloidosis detected only at necropsy: comparison with cases diagnosed in life. Arg Bras Cardiol 2008;90(3):191-196.

  12. Sipe JD, Benson MD, Buxbaum JN, et al, and the Nomenclature Committee of the International Society of Amyloidosis. Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012;19(4):167-70. doi: 10.3109/13506129.2012.734345.

  13. Foli A, Palladini G, Caporali R, et al. The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 2011;18(1):80- 82. doi: 10.3109/13506129.2011.574354029.

  14. Schönland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012;119(2):488-493. doi: 10.1182/blood-2011-06-358507.

  15. Cheng ZW, Tian Z, Kang L, Chen TB, Fang LG, et al. Electrocardiographic and echocardiographic features of patients with primary cardiac amyloidosis. Zhonghua Xin Xue Guan Bing Za Zhi 2010;38(7):606-609.

  16. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50(22):2101-2110. doi: 10.1016/j.jacc.2007.08.028.

  17. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51(10):1022-1030. doi: 10.1016/j.jacc.2007.10.049.

  18. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole‐Wilson PA, Hawkins PN, Pennell DJ. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111(2):186-193. DOI: 10.1161/01. CIR.0000152819.97857.9D

  19. Kieninger B, Eriksson M, Kandolf R, Schnabel PA, Schonland S, et al. Amyloid in endomyocardial biopsies. Virchows Arch 2010;456(5):523-532.

  20. Nordlinger M, Magnani B, Skinner M, Falk RH. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 2005;96(7):982-984. doi: 10.1016/j.amjcard. 2005.05.057.

  21. Palladini G, Foli A, Milani P, Russo P, Albertini R, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012;87(5):465-471. doi: 10.1002/ajh.23141.

  22. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356(23):2361-71. doi: 10.1056/NEJMoa070265.

  23. Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356(23):2349-2360. doi: 10.1056/NEJMoa065644.




2020     |     www.medigraphic.com